These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced positive updated data from its THIO-101 ...

MAIA Biotechnology (MAIA) announced updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, THIO, ...

CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company with a market capitalization of $49.4 million, has announced updated data from its Phase 2 clinical ...

A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs like Ozempic, Wegovy and ...

GSK licensed the drug from long-standing partner Ionis as part of a two-drug deal in 2019, paying $25 million upfront with milestone payments taking the value of the deal up to $262 million.

Following a "short pursuit", a 41-year-old man, a 30-year-old man, and an 18-year-old man were searched and arrested on suspicion of possession with intent to supply class B drugs. A search of the ...

Drug-resistant infections occur when pathogens change in ways that render antimicrobial drugs ineffective. As a result, the pathogens survive and continue to spread. When infections are treatable with ...

Oxide nanoparticles, particularly iron oxide, ceria and silica nanoparticles, hold significant promise for biomedical applications owing to their unique magnetic, catalytic and porous properties ...

hot r&b songs the week’s most popular current r&b songs across all genres, ranked by streaming activity data by online music sources tracked by luminate, radio airplay audience impressions as ...

Drug development describes the process of developing a new drug that effectively targets a specific weakness in a cell. This process involves specific pre-clinical development and testing ...